{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:06:04Z","timestamp":1786964764097,"version":"build-2736575974"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11864-023-01094-z","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:04:53Z","timestamp":1684231493000},"page":"892-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Intersection of Prostate Cancer and Hypertension: a Call to Action"],"prefix":"10.1007","volume":"24","author":[{"given":"Elena","family":"Dolmatova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Michael","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Mandawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"issue":"9974","key":"1094_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","volume":"385","author":"M Quaresma","year":"2015","unstructured":"Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971\u20132011: a population-based study. Lancet. 2015;385(9974):1206\u201318.","journal-title":"Lancet"},{"issue":"1","key":"1094_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1094_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","volume":"29","author":"A Guha","year":"2019","unstructured":"Guha A, Armanious M, Fradley MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019;29(1):29\u201339.","journal-title":"Trends Cardiovasc Med"},{"issue":"18","key":"1094_CR4","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20200308","volume":"134","author":"KB Neves","year":"2020","unstructured":"Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci (Lond). 2020;134(18):2503\u201320.","journal-title":"Clin Sci (Lond)"},{"issue":"7","key":"1094_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","volume":"128","author":"DCH van Dorst","year":"2021","unstructured":"van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128(7):1040\u201361.","journal-title":"Circ Res"},{"issue":"11","key":"1094_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O\u2019Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1094_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238\u201344.","journal-title":"JAMA"},{"issue":"9932","key":"1094_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 125 million people. Lancet. 2014;383(9932):1899\u2013911.","journal-title":"Lancet."},{"issue":"12","key":"1094_CR9","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013492.","journal-title":"Circulation"},{"issue":"1","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"e0225207","DOI":"10.1371\/journal.pone.0225207","volume":"15","author":"SJ Forrester","year":"2020","unstructured":"Forrester SJ, Dolmatova EV, Griendling KK. An acceleration in hypertension-related mortality for middle-aged and older Americans, 1999\u20132016: An observational study. PLoS ONE. 2020;15(1):e0225207.","journal-title":"PLoS ONE"},{"issue":"1","key":"1094_CR11","first-page":"5","volume":"10","author":"T Grozescu","year":"2017","unstructured":"Grozescu T, Popa F. Prostate cancer between prognosis and adequate\/proper therapy. J Med Life. 2017;10(1):5\u201312.","journal-title":"J Med Life"},{"issue":"12","key":"1094_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1212\/WNL.0000000000001951","volume":"85","author":"HJ Fullerton","year":"2015","unstructured":"Fullerton HJ, Stratton K, Mueller S, Leisenring WW, Armstrong GT, Weathers RE, et al. Recurrent stroke in childhood cancer survivors. Neurology. 2015;85(12):1056\u201364.","journal-title":"Neurology"},{"issue":"3","key":"1094_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1094_CR14","unstructured":"Prostate Cancer Statistics | CDC.Center for Disease Control and Prevention. 2022 [cited 2023. Available from: https:\/\/www.cdc.gov\/cancer\/prostate\/statistics\/index.htm. Accessed 30 Dec 2022."},{"issue":"6","key":"1094_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","volume":"4","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877\u201392.","journal-title":"Eur Urol Oncol"},{"key":"1094_CR16","doi-asserted-by":"publisher","first-page":"31358","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.","journal-title":"Sci Rep"},{"issue":"5","key":"1094_CR17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/HJH.0000000000002006","volume":"37","author":"V Katsi","year":"2019","unstructured":"Katsi V, Magkas N, Georgiopoulos G, Athanasiadi E, Virdis A, Masi S, et al. Arterial hypertension in patients under antineoplastic therapy: a systematic review. J Hypertens. 2019;37(5):884\u2013901.","journal-title":"J Hypertens"},{"key":"1094_CR18","doi-asserted-by":"crossref","unstructured":"Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: An Emerging Specialty. Adv Chronic Kidney Dis. 2021;28(5):477\u201389 e1.","DOI":"10.1053\/j.ackd.2021.09.011"},{"issue":"10024","key":"1094_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377.","journal-title":"Lancet"},{"issue":"26","key":"1094_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374.","journal-title":"N Engl J Med"},{"issue":"32","key":"1094_CR21","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1094_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351.","journal-title":"N Engl J Med"},{"issue":"4","key":"1094_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"issue":"10323","key":"1094_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"key":"1094_CR25","first-page":"129","volume":"7","author":"JF Lester","year":"2015","unstructured":"Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf. 2015;7:129\u201338.","journal-title":"Drug Healthc Patient Saf"},{"issue":"16","key":"1094_CR26","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","volume":"144","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295\u2013307.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"1094_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1472-6483(11)60210-1","volume":"5","author":"O Ortmann","year":"2002","unstructured":"Ortmann O, Weiss JM, Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1\u20137.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"1094_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195\u2013201.","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"1094_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1094_CR30","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/0026-0495(90)90190-N","volume":"39","author":"JA Tayek","year":"1990","unstructured":"Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39(12):1314\u20139.","journal-title":"Metabolism"},{"key":"1094_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fonc.2018.00543","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective analysis of patients with prostate cancer initiating GnRH agonists\/antagonists therapy using a german claims database: epidemiological and patient outcomes. Front Oncol. 2018;8:543.","journal-title":"Front Oncol"},{"key":"1094_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/TCRM.S249208","volume":"16","author":"V Perrone","year":"2020","unstructured":"Perrone V, DegliEsposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393\u2013401.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"1094_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bju.15059","volume":"126","author":"EB Cone","year":"2020","unstructured":"Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126(1):9\u201310.","journal-title":"BJU Int"},{"issue":"23","key":"1094_CR34","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187\u201396.","journal-title":"N Engl J Med"},{"key":"1094_CR35","unstructured":"Patel S. Mechanism and predictors of cardiotoxicity after prostate cancer treatment: a parallel cohort and randomized trial comparing radiation alone, radiation plus leuprolide, and radiation plusrelugolix 2022 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05320406. Accessed 30 Dec 2022."},{"key":"1094_CR36","unstructured":"GmbH MS.Relugolix versus leuprolide in patients with prostate cancer: a randomized, open-label study to assess major adverse cardiovascular events (REPLACE-CV) 2022 [Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05605964. Accessed 30 Dec 2022."},{"issue":"3","key":"1094_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1677\/joe.0.1780373","volume":"178","author":"CJ Malkin","year":"2003","unstructured":"Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis\u2013immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003;178(3):373\u201380.","journal-title":"J Endocrinol"},{"issue":"6","key":"1094_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","volume":"22","author":"AA Challa","year":"2021","unstructured":"Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021;22(6):47.","journal-title":"Curr Treat Options Oncol"},{"key":"1094_CR39","unstructured":"Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3 Suppl 3(Suppl 3):S10\u20134."},{"issue":"5","key":"1094_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35(5):183\u201391.","journal-title":"Urol Oncol"},{"key":"1094_CR41","doi-asserted-by":"crossref","unstructured":"Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50 Suppl(Suppl):S352\u20137.","DOI":"10.1194\/jlr.R800099-JLR200"},{"key":"1094_CR42","unstructured":"AdministrationUFaD. FDA approves enzalutamide for metastatic castration-sensitive prostate cancer 2019 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer. Accessed 20 Dec 2022."},{"issue":"9","key":"1094_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1080\/07357907.2019.1670203","volume":"37","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wu S. Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis. Cancer Invest. 2019;37(9):478\u201388.","journal-title":"Cancer Invest"},{"key":"1094_CR44","unstructured":"Enzalutamide [package insert].Northbrook, IL; Astellas Pharma US, Inc; 2012. ."},{"issue":"1","key":"1094_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40885-022-00197-3","volume":"28","author":"X Zhu","year":"2022","unstructured":"Zhu X, Wu S. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. Clin Hypertens. 2022;28(1):14.","journal-title":"Clin Hypertens"},{"issue":"1","key":"1094_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ceca.2006.11.003","volume":"42","author":"JL Scragg","year":"2007","unstructured":"Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007;42(1):11\u20135.","journal-title":"Cell Calcium"},{"key":"1094_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40885-019-0116-x","volume":"25","author":"X Zhu","year":"2019","unstructured":"Zhu X, Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens. 2019;25:5.","journal-title":"Clin Hypertens"},{"issue":"3","key":"1094_CR48","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645\u201353.","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"1094_CR49","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","volume":"27","author":"JE Goodwin","year":"2012","unstructured":"Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27(7):1059\u201366.","journal-title":"Pediatr Nephrol"},{"issue":"7\u20138","key":"1094_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00431-003-1233-8","volume":"162","author":"E De Wachter","year":"2003","unstructured":"De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr. 2003;162(7\u20138):488\u20139.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"1094_CR51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/ajh\/7.12.1105","volume":"7","author":"F Fallo","year":"1994","unstructured":"Fallo F, Fanelli G, Cipolla A, Betterle C, Boscaro M, Sonino N. 24-hour blood pressure profile in Addison\u2019s disease. Am J Hypertens. 1994;7(12):1105\u20139.","journal-title":"Am J Hypertens"},{"issue":"3","key":"1094_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/07420529009056985","volume":"7","author":"A Piovesan","year":"1990","unstructured":"Piovesan A, Panarelli M, Terzolo M, Osella G, Matrella C, Paccotti P, et al. 24-hour profiles of blood pressure and heart rate in Cushing\u2019s syndrome: relationship between cortisol and cardiovascular rhythmicities. Chronobiol Int. 1990;7(3):263\u20135.","journal-title":"Chronobiol Int"},{"issue":"2","key":"1094_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00004872-198902000-00006","volume":"7","author":"Y Imai","year":"1989","unstructured":"Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Nihei M, et al. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. J Hypertens. 1989;7(2):113\u201320.","journal-title":"J Hypertens"},{"issue":"8","key":"1094_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/CS20080178","volume":"117","author":"R Aras-Lopez","year":"2009","unstructured":"Aras-Lopez R, Xavier FE, Ferrer M, Balfagon G. Dexamethasone decreases neuronal nitric oxide release in mesenteric arteries from hypertensive rats through decreased protein kinase C activation. Clin Sci (Lond). 2009;117(8):305\u201312.","journal-title":"Clin Sci (Lond)"},{"issue":"4","key":"1094_CR55","first-page":"127","volume":"65","author":"AM Birkenhager","year":"2007","unstructured":"Birkenhager AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med. 2007;65(4):127\u201331.","journal-title":"Neth J Med"},{"issue":"9","key":"1094_CR56","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.jdiacomp.2022.108270","volume":"36","author":"HO Hjortkjaer","year":"2022","unstructured":"Hjortkjaer HO, Persson F, Theilade S, Winther SA, Tofte N, Ahluwalia TS, et al. Non-dipping and higher nocturnal blood pressure are associated with risk of mortality and development of kidney disease in type 1 diabetes. J Diabetes Complications. 2022;36(9):108270.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"1094_CR57","doi-asserted-by":"publisher","first-page":"F1536","DOI":"10.1152\/ajprenal.00372.2019","volume":"317","author":"JR Ivy","year":"2019","unstructured":"Ivy JR, Jones NK, Costello HM, Mansley MK, Peltz TS, Flatman PW, et al. Glucocorticoid receptor activation stimulates the sodium-chloride cotransporter and influences the diurnal rhythm of its phosphorylation. Am J Physiol Renal Physiol. 2019;317(6):F1536\u201348.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"1094_CR58","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/HYPERTENSIONAHA.115.06977","volume":"67","author":"JR Ivy","year":"2016","unstructured":"Ivy JR, Oosthuyzen W, Peltz TS, Howarth AR, Hunter RW, Dhaun N, et al. Glucocorticoids induce nondipping blood pressure by activating the thiazide-sensitive cotransporter. Hypertension. 2016;67(5):1029\u201337.","journal-title":"Hypertension"},{"issue":"10","key":"1094_CR59","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1097\/01.hjh.0000182522.21569.c5","volume":"23","author":"RC Hermida","year":"2005","unstructured":"Hermida RC, Calvo C, Ayala DE, Fernandez JR, Covelo M, Mojon A, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23(10):1913\u201322.","journal-title":"J Hypertens"},{"issue":"5","key":"1094_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"21","key":"1094_CR61","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137.","journal-title":"Circulation"},{"issue":"18","key":"1094_CR62","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"16","key":"1094_CR63","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"10124","key":"1094_CR64","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.","journal-title":"Lancet"},{"issue":"12","key":"1094_CR65","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"10145","key":"1094_CR66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0140-6736(18)31542-3","volume":"392","author":"SG Al-Kindi","year":"2018","unstructured":"Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;392(10145):382\u20133.","journal-title":"Lancet"},{"key":"1094_CR67","doi-asserted-by":"crossref","unstructured":"Ana Oaknin LG, Anna Tinker, Renaud Sabatier, Jubilee Brown, Cara Mathews, Valentina Boni, Vanessa Samouelian, David O\u2019Malley, Andrea Jewell, Susana Banerjee, Grace Antony, Jennifer Veneris, Bhavana Pothuri. Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post hoc analysis from the GARNET trial. Annual Meeting on Women\u2019s Cancer; Phoenix, AZ2022.","DOI":"10.1016\/S0090-8258(22)01435-4"},{"issue":"8","key":"1094_CR68","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol. 2018;34(8):1059\u201368.","journal-title":"Can J Cardiol"},{"issue":"5","key":"1094_CR69","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/cancers14051145","volume":"14","author":"C Li","year":"2022","unstructured":"Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors-associated cardiotoxicity. Cancers (Basel). 2022;14(5):1145.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1094_CR70","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1094_CR71","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","volume":"25","author":"C Ji","year":"2019","unstructured":"Ji C, Roy MD, Golas J, Vitsky A, Ram S, Kumpf SW, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res. 2019;25(15):4735\u201348.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1094_CR72","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"key":"1094_CR73","unstructured":"Docetaxel [patient information leaflet]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2004."},{"issue":"1","key":"1094_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.seminoncol.2005.11.001","volume":"33","author":"R Ng","year":"2006","unstructured":"Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33(1):2\u201314.","journal-title":"Semin Oncol"},{"issue":"6","key":"1094_CR75","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0002-9343(02)01049-5","volume":"112","author":"E Grossman","year":"2002","unstructured":"Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479\u201386.","journal-title":"Am J Med"},{"issue":"19","key":"1094_CR76","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1094_CR77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.115.06722","volume":"67","author":"WC Cushman","year":"2016","unstructured":"Cushman WC, Whelton PK, Fine LJ, Wright JT Jr, Reboussin DM, Johnson KC, et al. SPRINT trial results: latest news in hypertension management. Hypertension. 2016;67(2):263\u20135.","journal-title":"Hypertension"},{"issue":"10","key":"1094_CR78","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041.","journal-title":"J Hypertens"},{"issue":"22","key":"1094_CR79","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"1094_CR80","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/jhh.2016.62","volume":"31","author":"YN Boutcher","year":"2017","unstructured":"Boutcher YN, Boutcher SH. Exercise intensity and hypertension: what\u2019s new? J Hum Hypertens. 2017;31(3):157\u201364.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1094_CR81","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00262-017-1985-z","volume":"66","author":"M Idorn","year":"2017","unstructured":"Idorn M, Thor SP. Exercise and cancer: from \u201chealthy\u201d to \u201ctherapeutic\u201d? Cancer Immunol Immunother. 2017;66(5):667\u201371.","journal-title":"Cancer Immunol Immunother"},{"key":"1094_CR82","doi-asserted-by":"crossref","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr., das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281\u201390.","DOI":"10.1016\/j.jacc.2018.02.049"},{"issue":"22","key":"1094_CR83","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"1094_CR84","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","volume":"124","author":"S Laurent","year":"2017","unstructured":"Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116\u201325.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1094_CR85","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537\u201341.","journal-title":"Circulation"},{"issue":"9","key":"1094_CR86","doi-asserted-by":"publisher","first-page":"E458","DOI":"10.5489\/cuaj.6685","volume":"14","author":"M Kenk","year":"2020","unstructured":"Kenk M, Gregoire JC, Cote MA, Connelly KA, Davis MK, Dresser G, et al. Optimizing screening and management of cardiovascular health in prostate cancer: a review. Can Urol Assoc J. 2020;14(9):E458\u201364.","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"1094_CR87","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.hfc.2016.12.010","volume":"13","author":"A Mandawat","year":"2017","unstructured":"Mandawat A, Williams AE, Francis SA. Cardio-oncology: the role of big data. Heart Fail Clin. 2017;13(2):403\u20138.","journal-title":"Heart Fail Clin"},{"issue":"18","key":"1094_CR88","doi-asserted-by":"publisher","first-page":"10617","DOI":"10.3390\/ijms231810617","volume":"23","author":"Z Liang","year":"2022","unstructured":"Liang Z, He Y, Hu X. Cardio-oncology: mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci. 2022;23(18):10617.","journal-title":"Int J Mol Sci."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01094-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01094-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01094-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T06:13:33Z","timestamp":1686809613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01094-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01094-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"12 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Elena Dolmatova declares that she has no conflict of interest. Nida Waheed declares that she has no conflict of interest. Brian Michael Olson declares that she has no conflict of interest. Sagar Patel declares that she has no conflict of interest. Anant Mandawat declares that she has no conflict of interest.AM, BMO, and SP report significant research support from the Prostate Cancer Foundation, Pfizer, and Myovant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}